BioSyent Inc. (CVE:RX - Get Free Report) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$11.02 and traded as low as C$10.99. BioSyent shares last traded at C$11.30, with a volume of 30,477 shares trading hands.
BioSyent Price Performance
The firm has a market cap of C$129.81 million, a PE ratio of 18.67 and a beta of 0.93. The firm has a fifty day simple moving average of C$11.02 and a two-hundred day simple moving average of C$10.22. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13.
BioSyent (CVE:RX - Get Free Report) last posted its quarterly earnings data on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, meeting the consensus estimate of C$0.13. The business had revenue of C$8.95 million during the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a return on equity of 20.88% and a net margin of 21.14%. Equities analysts predict that BioSyent Inc. will post 0.6944444 EPS for the current fiscal year.
Insider Buying and Selling
In other BioSyent news, Director Seyed Ahmad Ashrafi sold 2,320 shares of BioSyent stock in a transaction on Friday, September 20th. The stock was sold at an average price of C$10.95, for a total transaction of C$25,404.00. 33.65% of the stock is owned by corporate insiders.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Read More
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
